• Company
    • About Us
    • NIR Legacy
    • News
    • Careers
  • Products
    • EluNIR
    • EluNIR-PERL
  • Technologies
    • Flexx²
    • WiZeCell
    • eDes Coating
    • Quality Surface
    • Electrospinning
  • Innovation
    • Stenting and catheterization
      • IoNIR
      • ChampioNIR DES
    • Structural Heart
      • TAVR
      • Dedicated Sheath
    • Implantable Microsensors
      • Microsensors
  • Partnerships
    • Corporate Development
    • Distribution Opportunities
  • Clinical
  • Contact Us
    • Find a Distributor
  • English

NEWS

LATEST
May 5, 2020

Medinol Completes Enrollment of EluNIR-HBR Study

LEARN MORE
LATEST
Apr 4, 2020

Medinol Enrolls a First-in-Human Study of ChampioNIR® SFA Stent System

LEARN MORE
Jan 1, 2018

Medinol Announce First U.S. Commercial Implants of Innovative ...

LEARN MORE
Nov 11, 2017

Cordis Announce FDA Approval of the Innovative EluNIR™ Drug-Eluting ...

LEARN MORE
Oct 10, 2017

Medinol Ltd. Receives CE Mark for the EluNIR™ Ridaforolimus-Eluting ...

LEARN MORE
Dec 12, 2016

Medinol announces excellent clinical results for EluNIR, a novel Drug ...

LEARN MORE
Nov 11, 2016

Medinol Receives Approval from The Japanese PMDA to Begin Clinical ...

LEARN MORE
Oct 10, 2016

Study Finds Medinol’s Ridaforolimus-Eluting Stent Is Non-Inferior to ...

LEARN MORE
12❯
  • Company
    • About Us
    • NIR Legacy
    • News
    • Careers
  • Products
    • EluNIR
    • EluNIR-PERL
  • Technologies
    • Flexx²
    • WiZeCell
    • eDes Coating
    • Quality Surface
    • Electrospinning
  • Innovation
    • IoNIR
    • ChampioNIR DES
    • TAVR
    • Dedicated Sheath
    • Microsensors
  • Partnerships
    • Corp. Development
    • Distribution Opp.
  • Clinical
    • Contact Us
    • Find a Distributor

© 2022 Medinol. All Rights Reserved.

 - MKW1031-1

Privacy Policy

Created by Attractive

The website you have requested may contain information on products or uses of such products that are not approved in your country.
For specific product and country information please contact Medinol.

CONTINUE

Our website uses cookies to provide optimal performance and improve your viewing experience. Please accept cookies to continue.

Accept